Legato Capital Management’s Roivant Sciences ROIV Stock Holding History

Legato Capital Management’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.24M	Sell	44,856 -484	-1%	-$12.4K	0.11%	239
2025 Q4	$984K	Buy	45,340 +13,135	+41%	+$259K	0.08%	364
2025 Q3	$487K	Buy	+32,205	New	+$399K	0.05%	443
2024 Q1	–	Sell	-18,000	Closed	-$202K	–	607
2023 Q4	$202K	Sell	18,000 -46,763	-72%	-$456K	0.03%	529
2023 Q3	$756K	Buy	64,763 +4,403	+7%	+$49.8K	0.11%	301
2023 Q2	$608K	Buy	+60,360	New	+$540K	0.08%	376

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Legato Capital Management's ROIV Position: Q1 2026 in Review

Legato Capital Management reduced its Roivant Sciences (ROIV) stake by 1.1% in Q1 2026, selling an estimated $12.4K and leaving 44,856 shares worth $1.24M. The position accounts for 0.11% of the portfolio, ranked #239.

Legato Capital Management first reported a position in ROIV in Q2 2023 and has held it in 6 quarters since. 439 funds tracked by Wall St. Rank hold ROIV as of Q1 2026.

Legato Capital Management held 44,856 shares of Roivant Sciences worth $1.24M as of Q1 2026.
Legato Capital Management sold 484 Roivant Sciences shares in Q1 2026, an estimated $12.4K.
Roivant Sciences made up 0.11% of Legato Capital Management's portfolio in Q1 2026, its #239 holding.
Legato Capital Management first reported a position in Roivant Sciences in Q2 2023 and has held it in 6 quarters since.
439 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2026.

Based on Legato Capital Management's 13F filing for Q1 2026, filed 14 May 2026.